RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

Author(s):
Steg, P.G.; Mehta, S.R.; Jukema, J.W. (0000-0002-3246-8359); Lip, G.Y.H.; Gibson, C.M.; Kovar, F.; Kala, P.; Garcia-Hernandez, A.; Renfurm, R.W.; Granger, C.B.; RUBY-1 Investigators
Published
2011
Publication type
Article / Letter to editor
AnticoagulantAcute coronary syndromeSecondary preventionDarexaban
Date issued
2011-10-31
Language
English
Is part of
European Heart Journal (2011), Vol. 32, no. 20, p. 2541-2554
hdl
1887/108555
doi
10.1093/eurheartj/ehr334